A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment

被引：0

作者：

Vicier, Cecile ^{[1
,2
]}

Baciarello, Giulia ^{[1
]}

Arfi-Rouche, Julia ^{[3
]}

Massard, Christophe ^{[4
]}

Loriot, Yohann ^{[1
]}

Albiges, Laurence ^{[1
]}

Cojean-Zelek, Isabelle ^{[5
]}

Fizazi, Karim ^{[1
]}

机构：

[1] Gustave Roussy, Dept Canc Med, 114 Rue Edouard Valliant, F-94805 Villejuif, France

[2] Aix Marseille Univ, Inst Paoli Calmettes, Dept Med Oncol, Marseille, France

[3] Gustave Roussy, Dept Radiol, Villejuif, France

[4] Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France

[5] Ctr Intercommunal Creteil, Dept Med Oncol, Creteil, France

来源：

CLINICAL GENITOURINARY CANCER | 2019年 / 17卷 / 03期

关键词：

Chemotherapy; High dose chemotherapy; Non-seminomatous germ cell tumor; Orchiectomy; Testicular cancer; HIGH-DOSE CHEMOTHERAPY; PHASE-II TRIAL; SALVAGE TREATMENT; RANDOMIZED-TRIAL; CISPLATIN; PACLITAXEL; MULTICENTER; OXALIPLATIN; SURVIVAL;

D O I：

10.1016/j.clgc.2019.01.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：E485 / E487

页数：3

共 23 条

[1] Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206 [J].

Adra, N. ;

Einhorn, L. H. ;

Althouse, S. K. ;

Ammakkanavar, N. R. ;

Musapatika, D. ;

Albany, C. ;

Vaughn, D. ;

Hanna, N. H. .

ANNALS OF ONCOLOGY, 2018, 29 (01) :209-214

[2] Guidelines on Testicular Cancer: 2015 Update [J].

Albers, Peter ;

Albrecht, Walter ;

Algaba, Ferran ;

Bokemeyer, Carsten ;

Cohn-Cedermark, Gabriella ;

Fizazi, Karim ;

Horwich, Alan ;

Laguna, Maria Pilar ;

Nicolai, Nicola ;

Oldenburg, Jan .

EUROPEAN UROLOGY, 2015, 68 (06) :1054-1068

[3] Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer [J].

Bokemeyer, C ;

Gerl, A ;

Schöffski, P ;

Harstrick, A ;

Niederle, N ;

Beyer, J ;

Casper, J ;

Schmoll, HJ ;

Kanz, L .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :512-516

[4] Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors:: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T9313P) [J].

Culine, S. ;

Kerbrat, P. ;

Kramar, A. ;

Theodore, C. ;

ChevreauU, C. ;

Geoffrois, L. ;

Bui, N. B. ;

Peny, J. ;

Caty, A. ;

Delva, R. ;

Biron, P. ;

Fizazi, K. ;

Bouzy, J. ;

Droz, J. P. .

ANNALS OF ONCOLOGY, 2007, 18 (05) :917-924

[5] Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor [J].

De Giorgi, Ugo ;

Rosti, Giovanni ;

Aieta, Michele ;

Testore, Franco ;

Burattini, Luciano ;

Fornarini, Giuseppe ;

Naglieri, Emanuele ;

Lo Re, Giovanni ;

Zumaglini, Federica ;

Marangolo, Maurizio .

EUROPEAN UROLOGY, 2006, 50 (05) :1032-1039

[6] Phase II trial of gemcitabine in refractory germ cell tumors [J].

Einhorn, LH ;

Stender, MJ ;

Williams, SD .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :509-511

[7] A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors [J].

Feldman, Darren R. ;

Einhorn, Lawrence H. ;

Quinn, David I. ;

Loriot, Yohann ;

Joffe, Johnathan K. ;

Vaughn, David J. ;

Flechon, Aude ;

Hajdenberg, Julio ;

Halim, Abdel-Baset ;

Zahir, Hamim ;

Motzer, Robert J. .

INVESTIGATIONAL NEW DRUGS, 2013, 31 (04) :1016-1022

[8] Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors [J].

Fizazi, K ;

Culine, S ;

Kramar, A ;

Amato, RJ ;

Bouzy, J ;

Chen, I ;

Droz, JP ;

Logothetis, CJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (19) :3868-3876

[9] Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial [J].

Fizazi, K. ;

Gravis, G. ;

Flechon, A. ;

Geoffrois, L. ;

Chevreau, C. ;

Laguerre, B. ;

Delva, R. ;

Eymard, J. C. ;

Rolland, F. ;

Houede, N. ;

Laplanche, A. ;

Burcoveanu, D. ;

Culine, S. .

ANNALS OF ONCOLOGY, 2014, 25 (05) :987-991

[10] Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial [J].

Fizazi, Karim ;

Pagliaro, Lance ;

Laplanche, Agnes ;

Flechon, Aude ;

Mardiak, Josef ;

Geoffrois, Lionnel ;

Kerbrat, Pierre ;

Chevreau, Christine ;

Delva, Remy ;

Rolland, Frederic ;

Theodore, Christine ;

Roubaud, Guilhem ;

Gravis, Gwenaelle ;

Eymard, Jean-Christophe ;

Malhaire, Jean-Pierre ;

Linassier, Claude ;

Habibian, Muriel ;

Martin, Anne-Laure ;

Journeau, Florence ;

Reckova, Maria ;

Logothetis, Christopher ;

Culine, Stephane .

LANCET ONCOLOGY, 2014, 15 (13) :1442-1450

← 1 2 3 →